Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-000241-39
    Sponsor's Protocol Code Number:ID-054-304
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-08-07
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-000241-39
    A.3Full title of the trial
    A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects with aneurysmal subarachnoid hemorrhage (aSAH)
    Estudio fase 3 prospectivo, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de clazosentán en prevenir el deterioro clínico debido a isquemia cerebral tardía (ICT) en pacientes adultos con hemorragia subaracnoidea aneurismática (HSAa)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical research study with clazosentan to evaluate its effects on preventing complications due to the narrowing of the blood vessels (vasospasm) in the brain, caused by bleeding onto the surface of the brain
    Estudio de investigación clínica con clazosentan que evalua los efectos en la prevención de complicaciones debidas al estrechamiento de los vasos sanguineos (vasospasmo) en el cerebro causado por sangrado en la superficie cerebral
    A.4.1Sponsor's protocol code numberID-054-304
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIdorsia Pharmaceuticals Ltd
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportIdorsia Pharmaceuticals Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIdorsia Pharmaceuticals Ltd
    B.5.2Functional name of contact pointClinical Trial Disclosure Desk
    B.5.3 Address:
    B.5.3.1Street AddressHegenheimermattweg 91
    B.5.3.2Town/ cityAllschwil
    B.5.3.3Post code4123
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34658271136
    B.5.6E-mailclinical-trials-disclosure@idorsia.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/03/182
    D.3 Description of the IMP
    D.3.1Product nameClazosentan
    D.3.2Product code ACT-108475
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCLAZOSENTAN
    D.3.9.1CAS number 180384-56-9
    D.3.9.2Current sponsor codeACT-108475
    D.3.9.3Other descriptive nameCLAZOSENTAN
    D.3.9.4EV Substance CodeSUB25412
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Aneurysmal Subarachnoid Hemorrhage
    hemorragia subaracnoidea aneurismática
    E.1.1.1Medical condition in easily understood language
    When a brain aneurysm (bulge) ruptures, it causes bleeding into the compartment surrounding the brain, the subarachnoid space and is therefore also known as aneurysmal subarachnoid hemorrhage (aSAH)
    Al romperse un aneurisma cerebral (bulto), hay sangrado en el espacio que rodea el cerebro, espacio subaracnoideo y, por ello, también se conoce como hemorragia subaracnoidea aneurismática (aSAH)
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10039330
    E.1.2Term Ruptured cerebral aneurysm
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10042316
    E.1.2Term Subarachnoid haemorrhage
    E.1.2System Organ Class 10022117 - Injury, poisoning and procedural complications
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To determine the efficacy of clazosentan in preventing clinical deterioration due to DCI, in subjects with aSAH.
    - Determinar la eficacia de clazosentán para prevenir el deterioro clínico debido a una ICT en pacientes con HSAa.
    E.2.2Secondary objectives of the trial
    - To evaluate the effect of clazosentan on the incidence of all-cause new or worsened cerebral infarction > or = 5 cm3 in total volume at Day 16 post-study drug initiation
    - To evaluate the effect of clazosentan on long-term clinical outcome, cognition, and health-related quality of life at Week 12 post-aSAH.
    - To evaluate the safety and tolerability of clazosentan in the selected population up to 24 hours post-study drug discontinuation.
    - Evaluar el efecto de clazosentán en la incidencia de la aparición o el empeoramiento por cualquier motivo de infarto cerebral con un volumen total > o = 5 cm3 el día 16 tras el inicio del tratamiento con el fármaco del estudio.
    - Evaluar el efecto de clazosentán en el resultado clínico a largo plazo, el conocimiento y la calidad de vida en términos médicos la semana 12 tras la HSAa.
    - Evaluar la seguridad y la tolerabilidad de clazosentán en la población seleccionada hasta 24 horas después de dejar el fármaco del estudio.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Written informed consent to participate in the study must be obtained from the subject or proxy/legal representative at any time from hospital admission to prior to initiation of any study-mandated procedure
    2. Males and females aged 18 to 70 years (inclusive, at hospital admission)
    3. Subjects with a ruptured saccular aneurysm, angiographically confirmed by DSA or CTA, which has been successfully secured within 72 hours of rupture, by surgical clipping or endovascular coiling
    4. WFNS (World Federation of Neurosurgical Societies) grades 1–4 (based on Glasgow Coma Scale [GCS]) assessed after recovery from the aneurysm-securing procedure and after external ventricular drainage for hydrocephalus, if required
    5. Subjects must meet one of the two following inclusion criteria:

    A) High-risk prevention: Subjects with a "thick and diffuse clot" (thick and diffuse is defined as a thick confluent clot, more than 4 mm in thickness, involving 3 or more basal cisterns) on the hospital admission CT scan, absence of cerebral vasospasm at the time of randomization, and possibility to start study drug in the ICU (or equivalent environment where all protocol assessments can be performed and the Patient Management Guidelines followed), within 96 hours after the time of the aneurysm rupture.
    OR
    B) Early treatment: Subjects without a thick and diffuse clot on the hospital admission CT scan who develop asymptomatic or minimally symptomatic moderate to severe angiographic vasospasm, within the 14-day period post-aneurysm rupture, and for whom it is possible to start study drug in the ICU (or equivalent environment where all protocol assessments can be performed and the Patient Management Guidelines followed), within 24 hours of this angiographic diagnosis.

    6. Presence of a cerebral CT scan, performed at least 8 hours post-aneurysm-securing procedure and within 24 hours prior to randomization, which rules out a significant (e.g., symptomatic) new or worsened cerebral infarct or re-bleeding of the repaired aneurysm.

    7. A woman of childbearing potential is eligible only if the pregnancy test performed during the screening period is negative.
    1. Para participar en el estudio, debe obtenerse el consentimiento informado por escrito del paciente o de su tutor o representante legal en cualquier momento a partir del ingreso en el hospital y antes de empezar cualquier procedimiento del estudio.
    2. Hombres y mujeres de entre 18 y 70 años (ambos incluidos, al ingreso hospitalario)
    3. Pacientes con una ruptura de aneurisma sacular, confirmada angiográficamente por medio de una angiografía de substracción digital (ASD) o una angiografía por tomografía computarizada (ATC), que se ha reparado en un plazo de 72 horas desde la ruptura, mediante un recorte quirúrgico o un embolismo endovascular.
    4. Grados de WFNS del 1 al 4 (según la escala Glasgow Coma Scale [GCS]) evaluados tras la recuperación del procedimiento de reparación del aneurisma y después de un drenaje ventricular externo para hidrocefalia, si es necesario.
    5. Los pacientes deben cumplir uno de los dos criterios de inclusión siguientes:
    A) Prevención de alto riesgo: pacientes con un "coágulo grueso y difuso" que se observa en la tomografía computarizada realizada al ingresar en el hospital, ausencia de vasoespasmo cerebral en el momento de la aleatorización y posibilidad de empezar a recibir el fármaco del estudio en la unidad de cuidados intensivos (UCI, o en el entorno equivalente donde se pueden llevar a cabo todas las evaluaciones del protocolo y se pueden seguir las directrices de gestión de pacientes), en un plazo de 96 horas tras la ruptura del aneurisma.
    O
    B) Tratamiento anticipado: pacientes que no presentan un "coágulo grueso y difuso" en la tomografía computarizada que se realiza al ingresar en el hospital y que desarrollan, de forma asintomática o mínimamente sintomática, vasoespasmo angiográfico de moderado a grave, en un plazo de 14 días tras las ruptura del aneurisma, y para los que es posible empezar el tratamiento con el fármaco del estudio en la UCI (o en el entorno equivalente donde se pueden llevar a cabo todas las evaluaciones del protocolo y se pueden seguir las directrices de gestión de pacientes), en las 24 horas posteriores a este diagnóstico por angiografía.

    6. Presencia de una TC cerebral, realizada al menos 8 horas tras el procedimiento de reparación del aneurisma y en un plazo de 24 horas anterior a la aleatorización, que descarta un nuevo e importante infarto cerebral (p. ej., sintomático) o el empeoramiento de este o una nueva hemorragia en el aneurisma reparado.

    7. Las mujeres con capacidad para quedarse embarazadas pueden participar siempre y cuando el resultado de la prueba de embarazo en suero realizada durante el periodo de selección sea negativo.
    E.4Principal exclusion criteria
    aSAH, aneurysm-securing procedure, vasospasm:

    1. Subjects with SAH due to causes other than a saccular aneurysm (e.g., trauma or rupture of fusiform or mycotic aneurysms, SAH associated with arterio-venous malformation, vertebral dissections).
    2. Significant bleeding post aneurysm-securing procedure (e.g., due to intra-ventricular drain, intra-cerebral hemorrhage, epidural hematoma, vessel dissection or rupture, re-bleeding of the repaired aneurysm), based on investigator judgment.
    3. Intra-or peri-aneurysm securing procedure complication requiring non-routine medical or interventional treatment such as administration of an antithrombotic or anti-platelet agent (e.g., abciximab), which is not completely resolved prior to randomization.
    4. Intraventricular hemorrhage on the hospital admission CT scan, filling more than 50% of both lateral ventricles and with involvement of the 3rd and 4th ventricles.
    5. Intracerebral hemorrhage on the hospital admission CT scan, with an approximate volume of > 50 mL.
    6. Presence of cerebral vasospasm at hospital admission (initial admission or transfer from another hospital) believed to be associated with a prior bleed (i.e., occurring before the bleed for which the subject is currently hospitalized). Vasospasm occurring during the aneurysm-securing procedure is not an exclusion criterion.

    Neurological and functional status:

    7. Subjects with a new major neurological deficit occurring post aneurysm-securing procedure which is attributable to the procedure and does not improve to pre-procedure status before randomization.
    8. Subjects with a GCS score of < or = 9 at the time of randomization and without intracranial pressure (ICP) monitoring.
    9. modified Rankin Score of 3 or higher, prior to the aSAH (i.e., due to a chronic condition).

    Other clinical considerations:

    10. Subjects with total bilirubin > 2 times the upper limit of normal, and/or a known diagnosis or clinical suspicion of liver cirrhosis or moderate to severe hepatic impairment
    11. Hypotension (systolic blood pressure [SBP] < or = 90 mmHg) at time of randomization that is refractory to treatment.
    12. Unresolved pulmonary edema or significant pneumonia still present at the time of randomization, or severe hypoxia at the time of randomization in intubated subjects, defined as PaO2/FiO2< or = 200.
    13. High sustained ICP (> 25 mmHg lasting > 20 minutes) at time of randomization, despite optimal treatment, in subjects with ICP monitoring.
    14. Severe cardiac failure requiring inotropic support at the time of randomization.
    HSAa, procedimiento de reparación del aneurisma, vasoespasmo:
    1. Pacientes con hemorragia subaracnoidea (HSA) debida a causas distintas de un aneurisma sacular (p. ej., traumatismo o ruptura de aneurismas fusiformes o micóticos, HSA asociada con una malformación arteriovenosa, disecciones vertebrales).
    2. Importante hemorragia tras el procedimiento de reparación del aneurisma (p. ej., debido a drenaje intraventricular, hemorragia intracerebral, hematoma epidural, disección o ruptura de vasos, nueva hemorragia del aneurisma reparado), según el criterio del investigador.
    3. Complicación del procedimiento de reparación en el aneurisma o alrededor de este que requiera tratamiento médico no rutinario o intervencionista tal como la administración de un agente antitrombótico o antiplaquetario (p. ej., abciximab), que no se haya resuelto por completo antes de la aleatorización.
    4. Presencia de hemorragia intraventricular en la TC realizada al ingresar en el hospital en más del 50 % de ambos ventrículos laterales y que afecten al 3r y al 4º ventrículo.
    5. Presencia de hemorragia intracerebral en la TC realizada al ingresar en el hospital con un volumen aproximado de > 50 mL.
    6. Presencia de vasoespasmo cerebral al ingresar en el hospital (primer ingreso o traslado de otro hospital) que se cree que puede estar relacionado con una hemorragia anterior (es decir, que se ha producido antes de la hemorragia por la que el paciente está hospitalizado en estos momentos). El vasoespasmo que se produce durante el procedimiento de reparación del aneurisma no es un criterio de exclusión

    Estado neurológico y funcional:
    7. Pacientes con un nuevo déficit neurológico importante que se produce tras el procedimiento de reparación del aneurisma atribuible al procedimiento y que no mejora el estado previo al procedimiento antes de la aleatorización.
    8. Pacientes con una puntuación de GCS < o = 9 en el momento de la aleatorización y sin supervisión de la presión intracraneal.
    9. Puntuación de 3 o superior en la mRS (Modified Rankin Scale) antes de la HSAa (es decir, a causa de una afección crónica).

    Otras consideraciones clínicas:
    10. Pacientes con una bilirrubina total de > 2 veces el límite superior de la normalidad, o con un diagnóstico conocido o sospecha clínica de cirrosis hepática o insuficiencia hepática de moderada a grave.
    11. Hipotensión (presión sanguínea sistólica < o = 90 mmHg) en el momento de la aleatorización resistente al tratamiento.
    12. Edema pulmonar sin resolver o neumonía importante presente en el momento de la aleatorización o hipoxia grave en el momento de la aleatorización en pacientes intubados, definida como PaO2/FiO2 < o = 200.
    13. Presión intracraneal alta sostenida (> 25 mmHg durante > 20 minutos) en el momento de la aleatorización, a pesar del tratamiento óptimo, en pacientes con supervisión de la presión intracraneal.
    14. Insuficiencia cardiaca grave que requiere apoyo inotrópico en el momento de la aleatorización.
    E.5 End points
    E.5.1Primary end point(s)
    - Occurrence of clinical deterioration due to DCI from study drug initiation up to 14 days post-study drug initiation
    - la incidencia de deterioro clínico debido a la ICT desde el inicio del tratamiento con el fármaco del estudio hasta que transcurran 14 días.
    E.5.1.1Timepoint(s) of evaluation of this end point
    From study drug initiation up to 14 days post-study drug initiation
    Desde el incio del tratamiento hasta que trascurran 14 días
    E.5.2Secondary end point(s)
    1- Main secondary endpoint:
    Occurrence of all-cause new or worsened cerebral infarction > or = 5 cm3 (total volume) at Day 16 post study drug initiation

    2- Other secondary endpoint:
    Long-term clinical outcome assessed by the Glasgow Outcome Scale Extended (GOSE) at Week 12 post-aSAH, dichotomized as follows: poor outcome (score < or = 4) and good outcome (score > 4)
    1- Criterio secundario de valoración principal:
    La aparición o el empeoramiento por cualquier motivo de infarto cerebral con un volumen total > o = a 5 cm3 el día 16 tras el inicio del tratamiento con el fármaco del estudio.
    2-Otro criterio de valoración secundario:
    Resultado clínico a largo plazo evaluado por la GOSE (Glasgow Outcome Scale Extended) en la semana 12 tras la HSAa, clasificado entre mal resultado (puntuación < o = 4) y buen resultado (puntuación < 4).
    E.5.2.1Timepoint(s) of evaluation of this end point
    1- At Day 16 post study drug initiation
    2- At Week 12 post-aSAH
    1- El día 16 tras el inicio del tratamiento
    2- En la semana 12 tras la HSAa
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of life
    Biomarkers
    Calidad de vida
    Biomarcadores
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA66
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Canada
    Czech Republic
    Denmark
    Finland
    France
    Germany
    Hungary
    Israel
    Italy
    Korea, Republic of
    Poland
    Spain
    Sweden
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of the trial is defined as last subject last visit (LSLV)
    El final del estudio será la última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months27
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months27
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 250
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Written inform consent must be obtained from the subject or proxy/legal representative, according to local regulations
    El consentimiento informado por escrito se debe obtener del paciente o allegado/representante legal, según regulaciones locales
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 264
    F.4.2.2In the whole clinical trial 400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-08-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-06-22
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-11-18
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 22:31:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA